Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Epidemiology of TB in 21st century
- Estimated TB incidence rates, 2010
- Countries with XDR-TB confirmed cases
- Global plan to stop TB: 2006 - 2015
- Bacille Calmette-Guerin
- Efficacy of BCG
- BCG protective efficacy – meta analysis
- Why doesn’t BCG work?
- Environmental mycobacteria: evidence for masking
- Blocking
- Other problems with BCG
- Tuberculosis in humans
- What do we know about protective immunity
- Design of an improved vaccine against TB
- Recombinant BCG strains
- Attenuated M.tb strains
- Booster vaccines: MTB 72F/M72
- Booster vaccines: SSI fusion proteins
- Booster vaccines: Aeras 402
- MVA85A
- Improving BCG induced protection by MVA85A
- Ag85A-specific cultured ELISPOT responses data
- In vitro Ag85A-induced IFN-g and IL-17 levels
- Stages of clinical development
- Robert Koch
- Design of studies with MVA85A
- Target populations
- Summary of MVA85A clinical trials since 2002
- Safety data
- BCG – MVA85A induced immune response
- CD4+ T cell epitopes recognised after vaccination
- Priming with BCG and boosting with MVA data
- MVA induced T cells are highly polyfunctional
- IL-17 and TB
- Antigen-85A specific IL-17 responses
- MVA85A in M.tb latently infected adults
- MVA85A in latently infected and in vaccinated
- Trials in South Africa
- MVA85A is immunogenic in South African trials
- Co-administration of MVA85A with EPI vaccines
- Infant Phase IIb efficacy trial
- Trials in HIV-infected adults
- HIV safety data
- MVA85A induces a polyfunctional profile
- Phase IIb trial in HIV-positive adults
- Progress
- Challenges
- Acknowledgements
- Funders and partners
Topics Covered
- Review of the current vaccine, BCG
- Potential reasons for variability
- Leading approaches to developing a new TB vaccine
- Clinical development of MVA85A
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
McShane, H. (2013, July 11). Global progress in TB vaccine development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 7, 2023, from https://hstalks.com/bs/2579/.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Helen McShane has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.